title: Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China.
abstract: OBJECTIVE
  Irritable Bowel Syndrome (IBS) has a substantial impact on health-related quality of life (HR-QoL) but high-quality data pre- and post-treatment using the IBS-Quality of Life (IBS-QOL) measure are limited. The objective of this study was to evaluate the changes from baseline of the IBS-QOL scores, symptom scores and health economic data in IBS patients, after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide.
  
  
  METHODS
  This was a prospective observational cohort study in patients with IBS, diagnosed using the Rome III criteria in four countries (Poland, Egypt, Mexico and China).
  
  
  RESULTS
  A total of 607 patients were enrolled. At baseline, the IBS-QOL total scores were 52.0 in Poland, 48.9 in Egypt, 51.9 in Mexico, 76.4 in China and 56.4 overall. Increases in IBS-QOL total score were statistically significant at Weeks 4 and 8 overall and in each country (overall: 11.8 at Week 4, 24.3 at Week 8; p < 0.001). Improvements were shown in all IBS-QOL subscales and scores. Symptoms and health economic outcomes were improved. Furthermore, the favourable safety profile of these treatments was confirmed in this study.
  
  
  CONCLUSIONS
  This study demonstrated that IBS patients have a substantially reduced HR-QoL and that treatment with mebeverine hydrochloride or pinaverium bromide improved HR-QoL.
authors.affiliation: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Hou
authors.forename: Shengliang
authors.initials: S
authors.lastname: Chen
authors.forename: Yali
authors.initials: Y
authors.lastname: Zhang
authors.forename: Weihong
authors.initials: W
authors.lastname: Sha
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Yu
authors.forename: Hesham
authors.initials: H
authors.lastname: Elsawah
authors.forename: Afifi Fahmy
authors.initials: AF
authors.lastname: Afifi
authors.forename: Hisham Raafat
authors.initials: HR
authors.lastname: El-Khayat
authors.forename: Alaa
authors.initials: A
authors.lastname: Nouh
authors.forename: Mohamed Fathalla
authors.initials: MF
authors.lastname: Hassan
authors.forename: Ayman Abdel
authors.initials: AA
authors.lastname: Fatah
authors.forename: Isabel
authors.initials: I
authors.lastname: Rucker Joerg
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Sánchez Núñez
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Osthoff Rueda
authors.forename: Grazyna
authors.initials: G
authors.lastname: Jurkowska
authors.forename: Michal
authors.initials: M
authors.lastname: Walczak
authors.forename: Ewa
authors.initials: E
authors.lastname: Malecka-Panas
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Linke
authors.forename: Marek
authors.initials: M
authors.lastname: Hartleb
authors.forename: Gwendolyn
authors.initials: G
authors.lastname: Janssen-van Solingen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002681:China; D015331:Cohort Studies; D004334:Drug Administration Schedule; D004534:Egypt; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000523:psychology*; D008297:Male; D008800:Mexico; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D010627:Phenethylamines / Q000008:administration & dosage / Q000627:therapeutic use*; D011044:Poland; D011446:Prospective Studies; D011788:Quality of Life; D055815:Young Adult
chemical_list: D009025:Morpholines; D010627:Phenethylamines; C005096:mebeverine; C013199:pinaverium